BPC-157 for Gut Health & Leaky Gut: What the Evidence Shows

BPC-157 (body protection compound-157) is a synthetic 15-amino-acid peptide originally isolated from human gastric juice — making the gut its most studied biological domain. Decades of animal research document impressive cytoprotection against NSAID-induced injury, colitis, fistulas, and anastomosis failure. Yet despite this preclinical depth, no human randomized controlled trial has tested BPC-157 for any gastrointestinal indication, and the "leaky gut" claim — perhaps its most widely marketed use — rests on animal intestinal-permeability data that has never been replicated in a controlled human study. This article maps what the evidence actually shows: the strongest preclinical gut story in peptide research, and the human evidence gap that means every claim must carry that caveat. See our BPC-157 guide for the companion overview of how it works and what it costs.

BPC-157's gut origins: a gastric peptide from the start

BPC-157 was first identified in the 1990s by Predrag Sikiric and colleagues at the University of Zagreb as a partial sequence of human gastric juice protein. Unlike many research peptides developed for a specific receptor target, BPC-157 emerged from the gut itself — which is why the stomach and intestines remain its most extensively studied organ system. The peptide's original name — body protection compound — reflects the broad cytoprotective effects first observed in gastric mucosa models. Over thirty years of preclinical work have since expanded that picture to the entire gastrointestinal tract: from esophagus to colon, including fistula healing and anastomosis repair^[2].

That preclinical breadth is real and notable by peptide-research standards. What it is not is human clinical evidence. Every controlled experiment documenting these GI effects was conducted in rats or mice under standardized laboratory injury models. The animal-to-human translational gap is a recurring theme in BPC-157 research and is explicitly acknowledged in recent systematic reviews^[7][8].

NSAID-induced gut injury: the most documented preclinical effect

The strongest single line of BPC-157 GI evidence involves non-steroidal anti-inflammatory drug (NSAID) toxicity. NSAIDs — including aspirin, ibuprofen, diclofenac, and indomethacin — damage the gastric and intestinal mucosa by inhibiting prostaglandin synthesis, disrupting the mucosal barrier, and increasing intestinal permeability. In animal models, BPC-157 consistently counteracts these effects. A 2020 study by Park et al. in Current Pharmaceutical Design demonstrated that BPC-157 "rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing cytoprotection" in rodents^[1], documenting both barrier protection and cellular recovery at the mucosal level. This is mechanistically coherent: the peptide modulates nitric oxide systems and VEGFR2 signaling in ways that support mucosal repair and microvascular integrity.

Lojo et al.'s 2016 PLoS One study extended this picture to a surgically challenging model — 24-hour short-bowel rats treated with diclofenac^[4]. In these animals, diclofenac produced gastrointestinal, liver, and brain lesions while worsening intestinal adaptation; BPC-157 counteracted each of these effects. That multi-organ protection in a combined surgical/pharmacological stress model illustrates why BPC-157 has attracted preclinical attention: it appears to act at multiple failure points simultaneously, rather than blocking a single pathway.

Colitis and IBD animal models

BPC-157 has been tested in rodent models of colitis using acetic acid, TNBS (2,4,6-trinitrobenzenesulfonic acid), and other chemical inducers of intestinal inflammation — the standard preclinical surrogates for inflammatory bowel disease (IBD). In these models, BPC-157 consistently reduces mucosal damage scores, inflammatory markers, and histological injury. Sikiric's group has published extensively on this across multiple decades, and the 2024 Inflammopharmacology review synthesizes that literature under the framework of GI cytoprotection and vascular protection, noting that BPC-157 counteracts the vascular and multiorgan failure associated with severe gut injury^[2].

It is important to be clear about what "IBD model" means and what it does not mean. Acetic acid colitis in rats is a useful research tool for studying intestinal inflammation. It is not the same as Crohn's disease or ulcerative colitis in a human patient with a complex immune history, comorbidities, and years of disease. No human with IBD has been treated with BPC-157 in a published clinical trial, and no animal-colitis result should be interpreted as evidence that BPC-157 will benefit a human with Crohn's or UC.

Fistula and anastomosis healing in animal models

Two of the more surgically relevant animal-model applications involve fistulas and intestinal anastomoses. A fistula is an abnormal connection between two body structures — a recognized complication of IBD, radiation, surgery, and trauma. Sikiric et al.'s 2020 review in Current Pharmaceutical Design documents BPC-157 therapy across multiple fistula types in animal models, arguing that the peptide promotes healing of cutaneous, esophageal, colocutaneous, and other fistulas in rats^[5]. Healing rates and inflammatory markers consistently favored BPC-157 over control conditions in those experiments.

Bajramagic et al.'s 2024 review in Pharmaceuticals specifically covers intestinal anastomosis therapy in rats — that is, the healing of surgically created intestinal connections^[3]. Anastomosis failure (leakage) is a serious surgical complication; anything that reliably improved anastomosis healing in humans would be clinically meaningful. The animal data across multiple experiments is consistent: BPC-157 improves anastomosis healing speed and strength in rats. Whether this translates to any clinical benefit remains entirely untested in humans.

The brain-gut axis: BPC-157's bidirectional signaling

A 2023 paper by Sikiric et al. in Pharmaceuticals proposes that BPC-157 may recover function along both the brain-gut axis (central nervous system influencing gut) and the gut-brain axis (gut influencing central nervous system)^[6]. The brain-gut axis is a well-established bidirectional communication network linking the enteric nervous system to the central nervous system via vagal, hormonal, and immune pathways. Disruption of this axis is implicated in IBS, functional dyspepsia, and stress-related GI symptoms. In animal experiments, BPC-157 modulated dopamine, serotonin, and nitric oxide systems in ways that affected both gastrointestinal motility and neurological outcomes simultaneously. This pleiotropic signaling profile is interesting mechanistically but remains entirely preclinical.

"Leaky gut" — real physiology, not a standalone diagnosis

"Leaky gut" or intestinal hyperpermeability is a real, measurable physiological phenomenon. The intestinal lining acts as a selective barrier — allowing nutrients to pass while blocking pathogens, toxins, and large molecules. This barrier is maintained by tight junctions between enterocytes. When those junctions break down (as happens with NSAIDs, alcohol, stress, certain infections, and inflammatory conditions), intestinal permeability increases, allowing larger molecules to transit the gut lining. This can be measured with lactulose/mannitol ratios and other validated assays.

What is not an established medical diagnosis is "leaky gut syndrome" as a distinct condition responsible for fatigue, food sensitivities, autoimmune disease, autism, depression, and other systemic complaints — a cluster of claims popular in wellness marketing. Mainstream gastroenterology recognizes increased intestinal permeability as a feature of certain conditions (Crohn's disease, celiac disease, critical illness) rather than a standalone diagnosis that can be treated in isolation. The American Gastroenterological Association and similar bodies have not endorsed "leaky gut syndrome" as a clinical entity.

BPC-157's relevance here is specific: in NSAID-injury animal models, it demonstrably stabilizes intestinal permeability at the tight-junction level^[1]. That is a real and measurable preclinical effect. What it does not establish is that BPC-157 reverses "leaky gut syndrome" in humans, reduces food sensitivities, or treats any of the systemic complaints attributed to intestinal hyperpermeability in wellness contexts. The leap from "stabilizes NSAID-induced permeability changes in rats" to "heals leaky gut in humans" is not supported by any published controlled evidence.

The human evidence gap

For all the depth of its preclinical GI literature, BPC-157 has not been tested in a single completed, published human randomized controlled trial for any gastrointestinal indication. No Phase I dose-finding study for GI use, no Phase II safety-and-efficacy trial for IBD or IBS or fistula healing, no registered ongoing trial that is known to be active. A 2025 multifunctionality review by Józwiak et al. in Pharmaceuticals confirmed this translational gap across all BPC-157 indications^[7]: an extensive preclinical literature paired with an essentially absent human clinical database.

The 2025 systematic review by Vasireddi et al. in the HSS Journal, though focused on orthopaedic sports medicine, explicitly identified BPC-157's popularity as outpacing its evidence base and flagged the reliance on unregulated, non-pharmaceutical-grade sources as a central safety concern^[8]. Those findings apply equally to gut-health use: people are obtaining grey-market BPC-157 on the basis of animal studies that — however consistent — have never been replicated in controlled human trials.